Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial
Dekkers, Bart GJ Kerstjens, Huib AM Breisnes, Helene W Leeming, Diana J Anthony, Richard M Frijlink, Henderik W van der Werf, Tjip S Kosterink, Jos GW Alffenaar, Jan-Willem C Akkerman, Onno W
Dekkers, Bart GJ
Kerstjens, Huib AM
Breisnes, Helene W
Leeming, Diana J
Anthony, Richard M
Frijlink, Henderik W
van der Werf, Tjip S
Kosterink, Jos GW
Alffenaar, Jan-Willem C
Akkerman, Onno W
Series / Report no.
Open Access
Type
Journal Article
Randomized Controlled Trial
Article
Randomized Controlled Trial
Article
Language
en
Date
2025-06-02
Research Projects
Organizational Units
Journal Issue
Title
Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial
Translated Title
Published in
J Infect Dis 2025; 231(5):e891-e900
Abstract
Adjunctive host-directed therapies that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis are being investigated. Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investigated whether azithromycin enhances resolution of systemic and pulmonary inflammation and decreases extracellular matrix-related tissue turnover in tuberculosis patients.
An open-label, randomized, controlled trial was performed. Adult patients with drug-susceptible, pulmonary tuberculosis aged above 18 years were randomly assigned to receive standard antituberculosis care or azithromycin 250 mg orally once daily in addition to standard care (SOC) for 28 days.
Twenty-eight patients were included within 4 weeks after initiating antituberculosis treatment. Twelve patients in both arms completed the trial. Participants were mostly young, male, had a history of smoking, and had no comorbidities. No differences in baseline characteristics were observed between the study arms. In blood, azithromycin treatment significantly enhanced the reduction of the tuberculosis marker interferon-γ-induced protein-10 (SOC plus azithromycin, -38% vs SOC alone, -24% vs SOC, P < .05) and the collagen type IV degradation product C4M (-26% vs -11%, P < .05). In sputum, treatment with azithromycin significantly reduced neutrophils (-24% vs 0%, P < .001), neutrophil elastase (-88% vs 75%, P < .01), and transforming growth factor-β (-86% vs -68%, P < .05). No significant effects were observed on other parameters. Treatment with azithromycin appeared to be safe.
The addition of azithromycin to standard antituberculosis treatment appears to diminish excess neutrophilic inflammation in patients with pulmonary tuberculosis. Clinical Trials Registration. NCT03160638.
An open-label, randomized, controlled trial was performed. Adult patients with drug-susceptible, pulmonary tuberculosis aged above 18 years were randomly assigned to receive standard antituberculosis care or azithromycin 250 mg orally once daily in addition to standard care (SOC) for 28 days.
Twenty-eight patients were included within 4 weeks after initiating antituberculosis treatment. Twelve patients in both arms completed the trial. Participants were mostly young, male, had a history of smoking, and had no comorbidities. No differences in baseline characteristics were observed between the study arms. In blood, azithromycin treatment significantly enhanced the reduction of the tuberculosis marker interferon-γ-induced protein-10 (SOC plus azithromycin, -38% vs SOC alone, -24% vs SOC, P < .05) and the collagen type IV degradation product C4M (-26% vs -11%, P < .05). In sputum, treatment with azithromycin significantly reduced neutrophils (-24% vs 0%, P < .001), neutrophil elastase (-88% vs 75%, P < .01), and transforming growth factor-β (-86% vs -68%, P < .05). No significant effects were observed on other parameters. Treatment with azithromycin appeared to be safe.
The addition of azithromycin to standard antituberculosis treatment appears to diminish excess neutrophilic inflammation in patients with pulmonary tuberculosis. Clinical Trials Registration. NCT03160638.